Myriad Genetics Inc Sample Contracts

Standard Contracts

AGREEMENT
Participation Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
AutoNDA by SimpleDocs
EXHIBIT 10.1
Lease Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
EXHIBIT 1.1 2,000,000 Shares MYRIAD GENETICS, INC. Common Stock $0.01 par value UNDERWRITING AGREEMENT
Underwriting Agreement • March 14th, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
SCHEDULE to the Master Agreement dated as of October 8, 1997 between
Master Agreement • November 14th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
RECITALS --------
Subordination Agreement • November 12th, 1998 • Myriad Genetics Inc • Services-commercial physical & biological research
CREDIT AGREEMENT dated as of June 30, 2023 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent ___________________________ JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as...
Credit Agreement • July 6th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

CREDIT AGREEMENT dated as of June 30, 2023 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), among MYRIAD GENETICS, INC., as Borrower, the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Issuing Bank.

Myriad Genetics, Inc. Common Stock Underwriting Agreement
Underwriting Agreement • November 13th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances

Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,470,588 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 970,588 additional shares (the “Optional Securities”) of common stock, par value $0.01 per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).

WITNESSETH:
Standstill Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
MYRIAD GENETICS, INC. INDENTURE Dated as of DEBT SECURITIES Trustee
Indenture • November 8th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

WHEREAS, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of unsecured debentures, notes, bonds or other evidences of indebtedness (the “Securities”) in an unlimited aggregate principal amount to be issued from time to time in one or more series as provided in this Indenture; and

CREDIT AGREEMENT dated as of August 31, 2016 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger
Credit Agreement • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

CREDIT AGREEMENT (this “Agreement”) dated as of August 31, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

RECITALS --------
Collaboration and License Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Utah
R E C I T A L S:
Lease Agreement • November 8th, 1996 • Myriad Genetics Inc • Services-commercial physical & biological research
Exhibit 10.9 COLLABORATIVE PRONET RESEARCH AND LICENSE AGREEMENT dated as of November 11, 1998
Collaborative Research and License Agreement • February 12th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
AutoNDA by SimpleDocs
EXHIBIT 10.36 RESEARCH COLLABORATION AND LICENSE AGREEMENT
Research Collaboration and License Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Myriad Genetics, Inc. 7,000,000 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • November 4th, 2005 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 7,000,000 shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,050,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock.” The Stock, including the Shares, will have attached thereto rights (the “Rights”) to purchase from the Company, upon the occurrence of certain events, a unit consisting of one one-hundredth of a share of the Company’s Series A Junior Participating Preferred Stock, $0.01 par value per

MYRIAD GENETICS, INC. INCENTIVE STOCK OPTION AGREEMENT
Incentive Stock Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

This Agreement sets forth the terms of the incentive stock option (“ISO”) grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement (the “Employee”).

NEXUS ON GRAND LEASE
Lease • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • California

This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and MYRIAD GENETICS, INC., a Delaware corporation ("Tenant").

PLEDGE AND SECURITY AGREEMENT
Pledge and Security Agreement • July 6th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

THIS PLEDGE AND SECURITY AGREEMENT (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) is entered into as of June 30, 2023 by and among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), MYRIAD GENETICS LABORATORIES, INC., a Delaware corporation, MYRIAD WOMEN’S HEALTH, INC., a Delaware corporation, ASSUREX HEALTH, INC., a Delaware corporation, GATEWAY GENOMICS, LLC, a Delaware limited liability company, any additional entities which become parties to this Security Agreement by executing a Security Agreement Supplement hereto in substantially the form of Annex I hereto (such additional entities, together with the Borrower, Myriad Genetics Laboratories, Inc., Myriad Women’s Health, Inc., Assurex Health, Inc. and Gateway Genomics, LLC, each a “Grantor”, and collectively, the “Grantors”), and JPMorgan Chase Bank, N.A., in its capacity as administrative agent (the “Administrative Agent”) for the

RECITALS
License Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
INDEMNIFICATION AGREEMENT
Indemnification Agreement • November 7th, 2018 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this ___ day of __________, by and between MYRIAD GENETICS, INC., a Delaware corporation (the “Corporation”), and ___________________________________________________ (“Agent”).

AGREEMENT ---------
Immunity Agreement • November 14th, 1996 • Myriad Genetics Inc • Services-commercial physical & biological research • New Jersey
Executive Retention Agreement
Executive Retention Agreement • February 7th, 2020 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah

THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and ________________________ (the “Executive”), is made as of ________________________, (the “Effective Date”).

3,400,000 Shares Myriad Genetics, Inc. COMMON STOCK, $0.01 par value UNDERWRITING AGREEMENT
Underwriting Agreement • June 4th, 2004 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York

Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. Incorporated (the “Underwriter”) 3,400,000 shares of its common stock, $0.01 par value per share (the “Firm Shares”). The Company also proposes to issue and sell to the Underwriter not more than an additional 510,000 shares of its common stock, $0.01 par value per share (the “Additional Shares”), if and to the extent that you shall have determined to exercise the right to purchase such shares of common stock granted to you in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of common stock, $0.01 par value per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Common Stock.”

SUBLEASE AGREEMENT
Sublease Agreement • July 7th, 2009 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah

change order. The cost of any change orders that are necessary to comply with applicable building codes and other laws shall be borne by Landlord, unless such change orders are necessitated only because of (1) other change orders requested by Tenant; (2) Tenant Finish Plans; (3) changes to Tenant Finish Plans; or (4) Tenant’s early occupancy to the Building prior to substantial completion of Landlord’s Work. Any change order shall be effective only when set forth on a written change order executed by Landlord, Tenant, and the Base Building General Contractor. By approving a change order, Tenant and Landlord shall agree to a delay in Substantial Completion and to the Target Date, as specified therein, if any.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!